Nephrotic syndrome

Nephrotic syndrome is a clinically important renal syndrome in the book’s account of hepatitis C virus infection, HIV infection, and kidney transplantation. It may appear as the presenting expression of glomerular disease, coexist with hematuria or hypertension, or signal injury to a renal allograft. The syndrome is therefore not treated as a diagnosis that identifies one single lesion: its meaning depends on the underlying process, which may include cryoglobulinemic membranoproliferative glomerulonephritis, HIV-associated nephropathy, or de novo glomerular disease after transplantation.

Definition and Clinical Presentation

Nephrotic syndrome is described principally through substantial protein loss in the urine, often accompanied by other evidence of glomerular dysfunction. In patients with mixed cryoglobulinemia associated with HCV infection, kidney disease can produce either nephrotic or non-nephrotic proteinuria, hematuria, and variable reductions in estimated glomerular filtration rate. Acute nephritic syndrome and nephrotic syndrome occur as the clinical presentation in approximately 25% and 20% of these patients, respectively. Purpura, arthralgias, and peripheral neuropathy may precede the renal manifestations by several years, so the appearance of nephrotic syndrome can represent a later renal phase of a systemic vasculitis rather than an isolated kidney disorder.

The syndrome also occurs in more heterogeneous forms. In HCV-infected patients with HIV, clinical presentation ranges from persistent non-nephrotic proteinuria and microscopic hematuria with preserved renal function to nephrotic syndrome, macroscopic hematuria, and acute renal failure. Among kidney transplant recipients with HCV-related membranoproliferative disease, hypertension, microhematuria, proteinuria, renal dysfunction, and sometimes nephrotic syndrome form the principal clinical pattern. The same outward syndrome can therefore correspond to slowly progressive disease, an acute inflammatory process, or injury threatening the transplanted kidney.

HCV-Related Glomerular Disease

HCV infection is identified as a major cause of mixed cryoglobulinemia, a systemic vasculitis involving the skin, nerves, vessels, and kidneys. The diagnosis requires detection of cryoglobulins, and HCV RNA is usually present in serum; hypocomplementemia and a positive rheumatoid factor may also be found. HCV is mainly associated with type II mixed cryoglobulinemia, while type I membranoproliferative glomerulonephritis, also called cryoglobulinemic glomerulonephritis, is the most frequent renal lesion. Nephrotic syndrome in this setting is consequently a clinical expression of immune-complex and cryoglobulin-mediated glomerular injury.

The pathological pattern helps explain the severity of the syndrome. Exudative or lobular membranoproliferative glomerulonephritis is associated with nephrotic and/or nephritic syndrome, whereas mesangioproliferative glomerulonephritis more often produces proteinuria and microscopic hematuria while renal function remains normal. Massive intraluminal thrombi, vasculitis, or both are more common in patients with acute nephritic syndrome and rapid progression toward kidney failure. Even when nephrotic syndrome is prominent, the clinical course is variable: renal disease slowly progresses in most patients but does not necessarily reach kidney failure despite persistent proteinuria and impaired renal function, and some cases with massive thrombi and vasculitis can reverse spontaneously.

HIV and Coinfection Contexts

HIV-associated nephropathy is a collapsing form of focal glomerulosclerosis that typically presents with nephrotic syndrome and, without treatment, rapid deterioration of renal function. It is particularly frequent among Black patients with HIV. Renal biopsy shows collapsing focal glomerulosclerosis, marked podocyte hypertrophy, and tubulointerstitial changes; immunofluorescence may show isolated IgM and C3 deposits, while electron microscopy does not show immune-complex deposits. The book emphasizes that expression of HIV genes can promote glomerulosclerosis, although genetic predisposition remains crucial to the development of HIV-associated nephropathy.

In patients coinfected with HCV and HIV, nephrotic syndrome requires careful attribution. Cryoglobulinemic membranoproliferative glomerulonephritis is the characteristic HCV-associated lesion and may show mesangial proliferation, double contours of glomerular capillaries, IgG, IgM, and C3 deposits, subendothelial electron-dense deposits, cryoglobulin thrombi occluding capillary lumens, and occasional vasculitis outside the glomeruli. Yet HIV infection can independently produce several immune-complex glomerular diseases with varied morphology and clinical manifestations. A renal biopsy is therefore important, when not contraindicated, because nephrotic syndrome alone cannot distinguish HCV-induced cryoglobulinemic disease from HIV-associated or other immune-complex lesions.

Nephrotic Syndrome After Kidney Transplantation

In renal allograft recipients, cryoglobulinemia is particularly frequent among patients with HCV infection and can cause heavy proteinuria and allograft dysfunction. One reported series involved seven patients, five of whom were HCV-positive, with type III cryoglobulinemia-associated membranoproliferative glomerulonephritis. Five developed de novo nephrotic syndrome, five had severe hypertension, one had nephritic syndrome, and one had increased serum creatinine. Weekly rituximab infusions, given for two to four weeks at a dose of 375 mg/m2 alongside standard immunosuppression, produced substantial renal improvement: nephrotic syndrome entered sustained remission in three patients, improved in two, and cryoglobulins cleared persistently in six. Severe infectious complications occurred in two patients, illustrating the cost of treating immune-mediated disease in an already immunosuppressed host.

HCV-infected renal allograft recipients are also prone to immune-complex-mediated glomerulonephritis resembling disease in nontransplanted patients. HCV-related membranoproliferative glomerulonephritis may occur with very low cryocrit levels, usually below 5%, even though HCV RNA is often much more concentrated in the cryocrit than in serum. The clinical picture includes hypertension, microhematuria, proteinuria, renal dysfunction, and sometimes nephrotic syndrome. Biopsy may show chronic injury in several renal compartments, focal or diffuse mesangial proliferation, double contours, and parietal IgM and C3 deposits. Electron microscopy can be necessary to distinguish membranoproliferative glomerulonephritis, which has subendothelial electron-dense deposits, from transplant glomerulopathy, which shows radiolucent areas in the glomerular basement membrane; both lesions can coexist.

Membranous glomerulonephritis is another possible cause of nephrotic syndrome in HCV-positive allografts. It is the most frequent type of de novo glomerulonephritis in HCV-negative renal allografts, and nephrotic syndrome is usually present. Unlike cryoglobulinemic membranoproliferative disease, however, a clear mechanism connecting HCV with membranous glomerulonephritis has not been established: cryoglobulins, immune complexes, and complement activation are usually absent. This uncertainty reinforces the need to separate the clinical syndrome from the pathological lesion rather than treating every instance of nephrotic syndrome in an HCV-positive recipient as proof of direct viral causation.

Diagnosis, Consequences, and Clinical Significance

The broader diagnostic framework begins by distinguishing HCV exposure from active infection. Anti-HCV antibodies indicate exposure, whereas detectable HCV RNA identifies active infection; chronic infection requires both anti-HCV and HCV RNA, with RNA detectable for more than six months. When nephrotic syndrome occurs in a patient with suspected HCV-related renal disease, clinicians must assess both the hepatic and extrahepatic effects of infection, including cryoglobulinemia-associated vasculitis. Liver fibrosis can be evaluated by biopsy or noninvasive methods such as FibroScan, but renal disease may still require kidney biopsy to establish the glomerular diagnosis.

The syndrome has consequences beyond urinary protein loss. In transplanted kidneys, de novo glomerular lesions occur in an estimated 5–15% of HCV renal allografts, and membranoproliferative glomerulonephritis is followed by membranous glomerulonephritis among the most frequent associated lesions in biopsies performed for cause. The diagnosis is clinically consequential because de novo glomerulonephritis is associated with accelerated graft loss. Patients who have already lost a graft to de novo HCV-related glomerulonephritis may develop an earlier and more aggressive form in subsequent transplants.

Management consequently targets the underlying disease rather than the syndrome alone. In HCV-associated disease, antiviral treatment may be considered, while rituximab can be attempted when cryoglobulinemia-associated membranoproliferative glomerulonephritis produces heavy proteinuria. Because interferon therapy can endanger renal allograft function, eradication of HCV before kidney transplantation is presented as a preventive strategy against post-transplant HCV-related disorders. Nephrotic syndrome thus functions in the book as both a visible clinical state and a warning sign: it can expose systemic viral activity, reveal immune-complex injury, and mark a renal allograft at heightened risk.